Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473185 | 0.90 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4470039 | 0.89 | MAPK14 (0.46) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL6859846 | 0.89 | MAPK14 (0.58) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL1065155 | 0.85 | MAPK14 (0.50) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14028120 | 0.83 | MAPK14 (0.48) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4463596 | 0.82 | MAPK14 (0.51) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL1061075 | 0.82 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL1063961 | 0.82 | HSP90AB1 (0.44) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4945708 | 0.81 | MAPK13 (0.38) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14534029 | 0.81 | MAPK14 (0.38) | MAPK14MAPK11MAPK13MAPK12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080268044-A1 | Novel Process and Formulations | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | claimed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080268044-A1 | Novel Process and Formulations | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20080268044-A1 | Novel Process and Formulations | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20080268044-A1 | Novel Process and Formulations | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007059500-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| EP-1499320-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1499320-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003088972-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268044-A1 | Novel Process and Formulations | UGT1A7, UGT2B7, CYP3A7 | MAPK14 2969/4885MAPK11 2124/4885MAPK13 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.